As we come to the end of Skin Cancer Awareness Month, Medicash, the UK’s largest provider of corporate health cash plans, is delighted to announce the renewal of its partnership with SkinVision, the innovative skin cancer screening app. Building on the last three years, this collaboration allows Medicash policyholders across the United Kingdom to continue benefiting from convenient and accessible skin health monitoring.
Skin cancer is a prevalent and potentially life-threatening condition. Early detection plays a vital role in successful treatment outcomes. To address this concern, Medicash initially introduced the SkinVision app in June 2020 as an added benefit to its corporate policyholders, later extending this to all policyholders. The response has been overwhelmingly positive, with users appreciating the app’s user-friendly interface and accuracy in identifying potential skin cancer risks.
To date Medicash policyholders have checked over 80,000 skin spots and moles with the SkinVision app. With 30.9% of all ‘high risk’ checks leading to clinical referrals, free access to SkinVision has meant that 308 Medicash customers have been recommended to access crucial early treatment for a variety of skin cancers – delivering better clinical outcomes for the patient and ultimately saving lives.
With the renewal of the partnership, Medicash reaffirms its commitment to the health and wellbeing of its policyholders. By providing continued access to the SkinVision app, Medicash empowers individuals to take proactive steps towards monitoring their skin health and detecting any changes or abnormalities promptly.
Neil, a Medicash policyholder said: “When I scanned a mole on my arm it flagged as ‘at risk’. After further investigation this was found to be a melanoma in situ which I’ve since had removed. I’m not the sort of person who goes to the doctor when they should, but this benefit makes the whole process so easy.”
The SkinVision app utilises advanced technology, including artificial intelligence and machine learning algorithms, to analyse images of the skin for signs of potential skin cancer. Through regular self-checks, users can capture images of their moles or skin lesions and receive instant risk assessments. The app also provides educational resources, enabling users to enhance their understanding of skin health and raise awareness about early detection.
“We are delighted to renew our partnership with SkinVision, reinforcing our commitment to supporting the health and wellbeing of our policyholders,” says Andy Roberts, Finance & IT Director at Medicash. “The SkinVision app empowers individuals to become more proactive in monitoring their skin health, leading to early detection and better treatment outcomes. We are proud to offer this valuable resource to all our policyholders across the UK.”
Medicash policyholders can access the SkinVision app at no additional cost, ensuring easy and convenient skin health monitoring from the comfort of their homes. This renewal underlines Medicash’s dedication to leveraging technology and innovative solutions to enhance the overall wellbeing of its policyholders.
Roosmarijn Rodenburg, Head of Marketing and Growth said: ”SkinVision is very happy that Medicash continues the partnership and sees the benefit of a cutting-edge technology to make early detection of high-risk skin spots easily accessible.
“It’s good to see that during our three-year partnership more than 80,000 skin checks have been performed in which several hundred possible skin cancers have been recognised that needed a medical follow-up. We look forward to working with Medicash going forward to drive awareness of skin cancer amongst its policyholders and detecting cancers early when they have the best chance for successful treatment.”
